Xuanhao Pharmaceutical

Xuanhao Pharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, focused on the discovery and development of innovative small molecule therapeutics for oncology. The company's research primarily targets hormone-driven cancers and key oncogenic signaling pathways to overcome existing drug resistance mechanisms. Its lead program, XH-101, is a next-generation, orally bioavailable selective estrogen receptor degrader (SERD) currently in Phase 1 clinical trials for the treatment of advanced breast cancer. In addition to its lead candidate, Xuanhao is advancing a pipeline of preclinical assets, including KRAS inhibitors and PROTAC-based protein degraders. The company leverages its proprietary drug discovery platform and internal R&D expertise to develop highly selective and potent therapies. Xuanhao aims to address significant unmet medical needs in the global oncology market through its differentiated pipeline.